Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Manipulation of MHC-I/TCR Interaction for Immune Therapy


Adoptive immunotherapy involving the transfer of autologous tumor or virus-reactive T lymphocytes has been demonstrated to be effective in the eradication of cancer and virally infected cells. Identification of MHC-restricted antigens and progress in generation of adaptive immune responses have provided new direction for such treatment for severe pathologies such as cancer and autoimmune diseases. Here we review the latest development about the molecular basis of MHC-I/TCR interaction, and its manipulation including enhanced MHC-I expression, modification of peptide and engineered TCR for clinical applications such as vaccine design, tumor therapy and autoimmune diseases.

Author information



Corresponding author

Correspondence to Bin Gao.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Liu, Q., Gao, B. Manipulation of MHC-I/TCR Interaction for Immune Therapy. Cell Mol Immunol 5, 171–182 (2008).

Download citation


  • MHC-I
  • TCR
  • MHC-I/TCR interaction
  • immune therapy

Further reading


Quick links